# Purdue Research Foundation

> Purdue Research Foundation is a VC fund backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: West Lafayette, United States
- Total investments: 8
- Last investment: Apr 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/purdue-research-foundation
- X (Twitter): http://twitter.com/PurdueRP
- Website: http://prf.org
- Facebook: http://www.facebook.com/Purdue-Research-Park/1645372169283

Purdue Research Foundation is a VC fund in West Lafayette focused on Biotechnology and Health Care. The mission of the Purdue Research Foundation is to advance Purdue University's quest for preeminence in discovery, learning, and engagement through effective stewardship of assets.The Foundation seeks to:1) Support Purdue's discovery, learning, and engagement priorities in close association with the University's strategicplan implementation and related administrative functions.2) Provide flexibility of resources for their agile deployment.3) Realize Purdue's technology transfer interests.4) Oversee Purdue's intellectual property management.5) Develop, manage, and deploy real estate and financial assets.6) Engage Purdue Research Park resources to support business incubation.7) Advance Purdue's role in economic development.

## Contacts

5 contacts available for Purdue Research Foundation. Shizune tracks 8 team members at Purdue Research Foundation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/purdue-research-foundation?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Health Care | 3 | 38% |
| Medical | 2 | 25% |
| Pharmaceutical | 2 | 25% |
| AgTech | 1 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Funding Round | 2 | 25% |
| Seed | 1 | 13% |
| Pre-Seed | 1 | 13% |
| Convertible Note | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brooke Beier | Senior Vice President, Commercialization | 1 | https://shizune.co/investors/profile/brooke-beier-8bd0 |
| Dan Hasler | President and Chief Entrepreneurial Officer | 0 | https://shizune.co/investors/profile/dan-hasler |
| David E. Ross | Founder & President | 0 | https://shizune.co/investors/profile/david-e-ross |
| Gregory W. Deason | Senior Vice President and Past Vice President | 1 | https://shizune.co/investors/profile/gregory-w-deason |
| Joseph B. Hornett | Senior Vice President, Treasurer and COO | 0 | https://shizune.co/investors/profile/joseph-b-hornett |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rhea Space | Rhea Space Activity (RSA) is an astrophysics start-up company in the science and technology industry. Specifically, RSA ideates and creates high-risk/high-reward R&D concepts to support U.S. national security objectives. RSA has developed various technologies in the fields of infrared satellites, directed energy, artificial intelligence,LIDAR, astroparticle physics, small satellites, cislunar operations, intelligence collection, autonomous underwater vehicles, and the F35 Lightning II. | $6M | Series A | Apr 16, 2026 |  |
| Adipo Therapeutics | Adipo Therapeutic is a biotechnology company that develops polymer-based nanotherapeutics. Its nanotherapeutics utilizes adipocyte browning technique to convert energy-storing bad fat cells into energy-burning good fat cells to transform the treatment of obesity and type 2 diabetes, enabling patients to lose bodyweight naturally and restoringmetabolic balance for millions of people living with diabetes. | $1.9M | Convertible Note | Jan 31, 2024 |  |
| Adipo Therapeutics | Adipo Therapeutic is a biotechnology company that develops polymer-based nanotherapeutics. Its nanotherapeutics utilizes adipocyte browning technique to convert energy-storing bad fat cells into energy-burning good fat cells to transform the treatment of obesity and type 2 diabetes, enabling patients to lose bodyweight naturally and restoringmetabolic balance for millions of people living with diabetes. | $1.9M | Convertible Note | Jan 31, 2024 |  |
| OmniVis | OmniVis is a leading biotechnology company that has developed an integrated platform to transform the speed, accuracy, and economics of pathogen detection, anywhere in the world. OmniVis’ ultrasensitive handheld device provides a low-cost solution to labor intensive lab testing, bringing accurate results directly to the source in under 30 minutes. | $380K | Seed | May 14, 2021 |  |
| Novosteo | Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created aproprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces. | $5.5M | Series A | Jan 13, 2021 |  |
| Animated Dynamics | BioDynamic Imaging delivers better drug assessment in three-dimensional (3D) living tissue samples, revealing a comprehensive phenotypic response that is more physiologically meaningful than from conventional 2D or monolayer screens. Our technique is label-free and probes up to 1 mm deep in living tissue to study drug response in heterogeneoustissue environments. BioDynamic Imaging converts all forms of functional cellular motions into contrast maps of cellular mechanisms of action. | $250K |  | May 28, 2019 |  |
| Confluence Pharmaceuticals | Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders. The company's current focus is advancing a novel drug discovery that improves social and communication impairments for individuals with Autism Spectrum Disorders and Fragile X Syndrome. | $250K |  | Dec 20, 2018 |  |
| Novosteo | Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created aproprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces. | $250K | Pre-Seed | Dec 20, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Elevate Ventures](https://shizune.co/investors/profile/elevate-ventures) — VC Fund, 3 deals together
- [IU Angel Network](https://shizune.co/investors/profile/iu-angel-network) — VC Fund, 2 deals together
- [VisionTech Partners](https://shizune.co/investors/profile/visiontech-angels) — VC Fund, 2 deals together
- [Abo Ventures](https://shizune.co/investors/profile/abo-ventures) — VC Fund, 1 deal together
- [Ali Capital](https://shizune.co/investors/profile/ali-capital) — VC Fund, 1 deal together
- [BioCrossroads](https://shizune.co/investors/profile/biocrossroads) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Purdue Research Foundation invest in?

Purdue Research Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Purdue Research Foundation?

Public channels for Purdue Research Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Purdue Research Foundation?

The team at Purdue Research Foundation includes Brooke Beier (Senior Vice President, Commercialization), Dan Hasler (President and Chief Entrepreneurial Officer) and David E. Ross (Founder & President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co